Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E.

Neurology. 2020 Jan 6. pii: 10.1212/WNL.0000000000008900. doi: 10.1212/WNL.0000000000008900. [Epub ahead of print]

PMID:
31907289
2.

Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome.

Pontoizeau C, Girard A, Mesbah H, Haumont LA, Devillers A, Tempescul A, Salaün PY, Lamy T, Le Jeune F, Palard-Novello X.

Clin Nucl Med. 2020 Feb;45(2):118-122. doi: 10.1097/RLU.0000000000002879.

PMID:
31876819
3.

Deceased Donor Kidney Transplantation in New Caledonia: A Unique Collaboration With Australia.

Delezire A, Celton JL, Touzain F, Biche V, Haidar F, Cantin JF, Tivollier JM, Mesguen C, Carceles O, Lamy T, Saidi K, Allen R, Chadban S, Gracey D, Laurence J, Verran D, Mawson J, Wyburn K, Quirin N.

Transplantation. 2020 Jan;104(1):1-3. doi: 10.1097/TP.0000000000002859. No abstract available.

PMID:
31876693
4.

Large granular lymphocytic and other rare lymphoid leukemias.

Lamy T, Loughran TP.

Best Pract Res Clin Haematol. 2019 Sep;32(3):193-195. doi: 10.1016/j.beha.2019.09.001. Epub 2019 Sep 4. No abstract available.

PMID:
31585619
5.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M.

Leukemia. 2019 Nov;33(11):2762-2766. doi: 10.1038/s41375-019-0575-9. Epub 2019 Sep 26. No abstract available.

PMID:
31558766
6.

Understanding Maladaptation by Uniting Ecological and Evolutionary Perspectives.

Brady SP, Bolnick DI, Barrett RDH, Chapman L, Crispo E, Derry AM, Eckert CG, Fraser DJ, Fussmann GF, Gonzalez A, Guichard F, Lamy T, Lane J, McAdam AG, Newman AEM, Paccard A, Robertson B, Rolshausen G, Schulte PM, Simons AM, Vellend M, Hendry A.

Am Nat. 2019 Oct;194(4):495-515. doi: 10.1086/705020. Epub 2019 Aug 27.

PMID:
31490718
7.

Causes of maladaptation.

Brady SP, Bolnick DI, Angert AL, Gonzalez A, Barrett RDH, Crispo E, Derry AM, Eckert CG, Fraser DJ, Fussmann GF, Guichard F, Lamy T, McAdam AG, Newman AEM, Paccard A, Rolshausen G, Simons AM, Hendry AP.

Evol Appl. 2019 Aug 13;12(7):1229-1242. doi: 10.1111/eva.12844. eCollection 2019 Aug. Review.

8.

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.

Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C.

Haematologica. 2020 Jan;105(1):e33-e36. doi: 10.3324/haematol.2019.223016. Epub 2019 Aug 1. No abstract available.

9.

Species insurance trumps spatial insurance in stabilizing biomass of a marine macroalgal metacommunity.

Lamy T, Wang S, Renard D, Lafferty KD, Reed DC, Miller RJ.

Ecology. 2019 Jul;100(7):e02719. doi: 10.1002/ecy.2719. Epub 2019 May 13.

PMID:
31081945
10.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
11.

Potential drug-drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay.

Sanchez L, Bacle A, Lamy T, Le Corre P.

Cancer Chemother Pharmacol. 2019 May;83(5):827-835. doi: 10.1007/s00280-019-03791-9. Epub 2019 Feb 13.

12.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
13.

Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.

Desmots F, Roussel M, Pangault C, Llamas-Gutierrez F, Pastoret C, Guiheneuf E, Le Priol J, Camara-Clayette V, Caron G, Henry C, Belaud-Rotureau MA, Godmer P, Lamy T, Jardin F, Tarte K, Ribrag V, Fest T.

Clin Cancer Res. 2019 Jan 15;25(2):735-746. doi: 10.1158/1078-0432.CCR-18-1153. Epub 2018 Oct 22.

14.

Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Moignet A, Lamy T.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:616-625. doi: 10.1200/EDBK_200689. Review.

15.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
16.

Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.

Norwood J, Pastoret C, Luycx O, Le Coz MF, Moreau P, Trebouet A, Niault M, Launay V, Allangba O, Bareau B, Doncker V, Grulois I, Jacomy D, Le Dû K, Henry C, Le Pabic E, Boulland ML, Fest T, Lamy T, Escoffre-Barbe M.

Am J Hematol. 2018 Oct;93(10):E329-E331. doi: 10.1002/ajh.25217. Epub 2018 Sep 30. No abstract available.

17.

Prospect for a 60 GHz multicharged ECR ion source.

Thuillier T, Bondoux D, Angot J, Baylac M, Froidefond E, Jacob J, Lamy T, Leduc A, Sole P, Debray F, Trophime C, Skalyga V, Izotov I.

Rev Sci Instrum. 2018 May;89(5):052302. doi: 10.1063/1.5017113.

PMID:
29864837
18.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G.

Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.

19.

Giant kelp, Macrocystis pyrifera, increases faunal diversity through physical engineering.

Miller RJ, Lafferty KD, Lamy T, Kui L, Rassweiler A, Reed DC.

Proc Biol Sci. 2018 Mar 14;285(1874). pii: 20172571. doi: 10.1098/rspb.2017.2571.

20.

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial.

Carras S, Dubois B, Senecal D, Jais JP, Peoc'h M, Quittet P, Foussard C, Bouabdallah K, Gastinne T, Jourdan E, Sanhes L, Ertault M, Lamy T, Molina L.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):191-198. doi: 10.1016/j.clml.2018.01.003. Epub 2018 Jan 31.

PMID:
29502594
21.

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlich PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1657-1663. doi: 10.1016/j.bbmt.2018.02.014. Epub 2018 Mar 1.

22.

Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, Sicre de Fontbrune F, Barraco F, Socié G.

Am J Hematol. 2018 May;93(5):635-642. doi: 10.1002/ajh.25050. Epub 2018 Feb 14.

23.

IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies.

Allain JS, Thonier F, Pihan M, Boulland ML, de Guibert S, Launay V, Doncker AV, Ganard M, Aliouat A, Pangault C, Houot R, De Tayrac M, Lamy T, Roussel M, Fest T, Decaux O, Pastoret C.

Haematologica. 2018 May;103(5):e207-e210. doi: 10.3324/haematol.2017.177444. Epub 2018 Jan 25. No abstract available.

24.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.

Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.

PMID:
29241979
25.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, Lamy T, Wynckel A, Kolb B, Royer B, Rabot N, Benboubker L, Combe C, Jaccard A, Moulin B, Knebelmann B, Chevret S, Fermand JP; MYRE Study Group.

JAMA. 2017 Dec 5;318(21):2099-2110. doi: 10.1001/jama.2017.17924.

26.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M; SPRINT Trial Investigators.

Br J Haematol. 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.

27.

Scale-specific drivers of kelp forest communities.

Lamy T, Reed DC, Rassweiler A, Siegel DA, Kui L, Bell TW, Simons RD, Miller RJ.

Oecologia. 2018 Jan;186(1):217-233. doi: 10.1007/s00442-017-3994-1. Epub 2017 Nov 3.

PMID:
29101467
28.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

29.

Bioinvasion Triggers Rapid Evolution of Life Histories in Freshwater Snails.

Chapuis E, Lamy T, Pointier JP, Juillet N, Ségard A, Jarne P, David P.

Am Nat. 2017 Nov;190(5):694-706. doi: 10.1086/693854. Epub 2017 Sep 5.

PMID:
29053358
30.

STAT3 mutation impacts biological and clinical features of T-LGL leukemia.

Teramo A, Barilà G, Calabretto G, Ercolin C, Lamy T, Moignet A, Roussel M, Pastoret C, Leoncin M, Gattazzo C, Cabrelle A, Boscaro E, Teolato S, Pagnin E, Berno T, De March E, Facco M, Piazza F, Trentin L, Semenzato G, Zambello R.

Oncotarget. 2017 Jun 27;8(37):61876-61889. doi: 10.18632/oncotarget.18711. eCollection 2017 Sep 22.

31.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group.

N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

32.

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.

Gay C, Delarue R, Milpied N, Oberic L, Coiffier B, Boussetta S, Haioun C, Tilly H, Salles G, Lamy T, Lester MA, Houot R.

Blood. 2017 May 18;129(20):2811-2813. doi: 10.1182/blood-2017-02-766147. Epub 2017 Mar 16. No abstract available.

33.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G.

Blood. 2017 May 11;129(19):2616-2623. doi: 10.1182/blood-2016-10-744292. Epub 2017 Mar 1.

34.

LGL leukemia: from pathogenesis to treatment.

Lamy T, Moignet A, Loughran TP Jr.

Blood. 2017 Mar 2;129(9):1082-1094. doi: 10.1182/blood-2016-08-692590. Epub 2017 Jan 23. Review.

35.

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Labouré G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link BK, Tarte K, Witzig TE, Lamy T, Slager SL, Roussel M, Milpied N, Cerhan JR, Fest T.

Leukemia. 2017 Apr;31(4):988-991. doi: 10.1038/leu.2016.385. Epub 2017 Jan 27. No abstract available.

36.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
37.

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.

Clin Cancer Res. 2017 May 1;23(9):2232-2244. doi: 10.1158/1078-0432.CCR-16-1922. Epub 2016 Dec 6.

38.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Br J Haematol. 2017 Jan;176(1):37-49. doi: 10.1111/bjh.14387. Epub 2016 Nov 11.

PMID:
27858991
39.

Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing.

Pastoret C, Houot R, Llamas-Gutierrez F, Boulland ML, Marchand T, Tas P, Ly-Sunnaram B, Gandemer V, Lamy T, Roussel M, Fest T.

Leuk Lymphoma. 2017 Apr;58(4):1008-1012. doi: 10.1080/10428194.2016.1225208. Epub 2016 Sep 23. No abstract available.

PMID:
27659839
40.

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.

Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G, Godmer P, Bouabdallah K, Milpied N, Damaj G, Tarte K, Fest T, Roussel M.

Blood. 2016 Aug 25;128(8):1081-92. doi: 10.1182/blood-2015-08-662783. Epub 2016 Jun 23.

41.

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G.

Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11.

PMID:
27080498
42.

CD1d-restricted peripheral T cell lymphoma in mice and humans.

Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L.

J Exp Med. 2016 May 2;213(5):841-57. doi: 10.1084/jem.20150794. Epub 2016 Apr 11.

43.

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H.

Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24.

PMID:
27010483
44.

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T.

Ann Oncol. 2016 Jul;27(7):1349-50. doi: 10.1093/annonc/mdw138. Epub 2016 Mar 21. No abstract available.

45.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

46.

ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis.

Costopoulos M, Touitou V, Golmard JL, Darugar A, Fisson S, Bonnemye P, Le Lez ML, Soussain C, Cassoux N, Lamy T, Le Hoang P, Bodaghi B, Merle-Béral H, Le Garff-Tavernier M.

Ophthalmology. 2016 Jul;123(7):1626-8. doi: 10.1016/j.ophtha.2016.01.037. Epub 2016 Mar 3. No abstract available.

47.

Optimizing charge breeding techniques for ISOL facilities in Europe: Conclusions from the EMILIE project.

Delahaye P, Galatà A, Angot J, Cam JF, Traykov E, Ban G, Celona L, Choinski J, Gmaj P, Jardin P, Koivisto H, Kolhinen V, Lamy T, Maunoury L, Patti G, Thuillier T, Tarvainen O, Vondrasek R, Wenander F.

Rev Sci Instrum. 2016 Feb;87(2):02B510. doi: 10.1063/1.4935229.

PMID:
26932063
48.

Charge breeder for the SPIRAL1 upgrade: Preliminary results.

Maunoury L, Delahaye P, Dubois M, Angot J, Sole P, Bajeat O, Barton C, Frigot R, Jeanne A, Jardin P, Kamalou O, Lecomte P, Osmond B, Peschard G, Lamy T, Savalle A.

Rev Sci Instrum. 2016 Feb;87(2):02B508. doi: 10.1063/1.4935215.

PMID:
26932061
49.

The new ECR charge breeder for the Selective Production of Exotic Species project at INFN--Laboratori Nazionali di Legnaro.

Galatà A, Patti G, Roncolato C, Angot J, Lamy T.

Rev Sci Instrum. 2016 Feb;87(2):02B503. doi: 10.1063/1.4933338.

PMID:
26932056
50.

Status of the SPIRAL2 injector commissioning.

Thuillier T, Angot J, Barué C, Bertrand P, Biarrotte JL, Canet C, Denis JF, Ferdinand R, Flambard JL, Jacob J, Jardin P, Lamy T, Lemagnen F, Maunoury L, Osmond B, Peaucelle C, Roger A, Sole P, Touzery R, Tuske O, Uriot D.

Rev Sci Instrum. 2016 Feb;87(2):02A733. doi: 10.1063/1.4935227.

PMID:
26931951

Supplemental Content

Support Center